Identification of BET Inhibitors (BETi) Against Solitary Fibrous Tumor (SFT) Through High-Throughput Screening (HTS)
RNA-seq (gene expression) · human · 17 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 17 samples: 6 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE322765_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1431440 and SRA study SRP680681. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 17 samples.
How we read this: 6 replicated groups read from 17 sample titles; they account for 17 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9558113 INT-SFT cells treated with vehicle control for 24 h, biological replicate 1 INT-SFT cells treated w…
- GSM9558114 INT-SFT cells treated with vehicle control for 24 h, biological replicate 2 INT-SFT cells treated w…
- GSM9558115 INT-SFT cells treated with vehicle control for 24 h, biological replicate 3 INT-SFT cells treated w…
- GSM9558116 INT-SFT cells treated with Mivebresib (50 nM) for 24 h, biological replicate 1 INT-SFT cells treated w…
- GSM9558117 INT-SFT cells treated with Mivebresib (50 nM) for 24 h, biological replicate 2 INT-SFT cells treated w…
- GSM9558118 INT-SFT cells treated with Mivebresib (50 nM) for 24 h, biological replicate 3 INT-SFT cells treated w…
- GSM9558119 INT-SFT cells treated with BMS-986158 (50 nM) for 24 h, biological replicate 2 INT-SFT cells treated w…
- GSM9558120 INT-SFT cells treated with BMS-986158 (50 nM) for 24 h, biological replicate 3 INT-SFT cells treated w…
- GSM9558121 IEC139 cells treated with vehicle control for 24 h, biological replicate 1 IEC139 cells treated wi…
- GSM9558122 IEC139 cells treated with vehicle control for 24 h, biological replicate 2 IEC139 cells treated wi…
- GSM9558123 IEC139 cells treated with vehicle control for 24 h, biological replicate 3 IEC139 cells treated wi…
- GSM9558124 IEC139 cells treated with Mivebresib (50 nM) for 24 h, biological replicate 1 IEC139 cells treated wi…
- GSM9558125 IEC139 cells treated with Mivebresib (50 nM) for 24 h, biological replicate 2 IEC139 cells treated wi…
- GSM9558126 IEC139 cells treated with Mivebresib (50 nM) for 24 h, biological replicate 3 IEC139 cells treated wi…
- GSM9558127 IEC139 cells treated with BMS-986158 (50 nM) for 24 h, biological replicate 1 IEC139 cells treated wi…
- GSM9558128 IEC139 cells treated with BMS-986158 (50 nM) for 24 h, biological replicate 2 IEC139 cells treated wi…
- GSM9558129 IEC139 cells treated with BMS-986158 (50 nM) for 24 h, biological replicate 3 IEC139 cells treated wi…
- GSE199939 Comprehensive transcriptomic analysis of immune-related genes in diabetic foot ulcers: New insights into mechanisms and therapeutic targets 21 samples shares bet, hts
- GSE280402 Deciphering the Transcriptomic Landscape of Type 2 Diabetes: Insights from Bulk RNA Sequencing and Single-Cell Analysis [RNA-seq] 16 samples shares bet, hts
- GSE278723 Differential Roles of Astrocytic CSF1 in Alzheimer's Disease and Cerebral Amyloid Angiopathy: Insights from Transcriptomic Analysis 248 samples shares hts
- GSE280267 Glycine Receptor Activity in β Cells Is Downregulated in Type 2 Diabetes and After High Glucose Culture 199 samples shares bet
- GSE319878 Interrogating the mechanistic link between neighborhood deprivation and colorectal cancer risk through gene expression analysis of normal colorectal biopsies 171 samples shares bet
- GSE296546 Diabetes mellitus is associated with a shared hyper-inflammatory immune response in melioidosis and tuberculosis patients: an observational case-control study 110 samples shares bet
- GSE253173 Coupling of response biomarkers between tumour and peripheral blood in patients undergoing chemoimmunotherapy II 100 samples shares bet
- GSE330843 The CRAC channel inhibitor Auxora interrupts inflammatory circuits between alveolar macrophages and T cells in patients with viral pneumonia 88 samples shares bet
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.